Participated · Seed · Jul 2024

ImmuneAGE Bio has built a drug-discovery platform that targets hematopoietic stem cells (HSCs) in the bone marrow to rejuvenate the entire immune system. The platform enables large-scale ex vivo combinatorial drug screening for geroprotective cocktails and reportedly achieves 1,000x expansion of HSCs, a >70x improvement over prior efforts. The company is advancing three programs: IA-101 (an oral small-molecule immune booster for respiratory infections and vaccine response in elderly patients), IA-201 (an ex vivo immune-rejuvenation cocktail for peripheral mobilized HSCs targeting chemotherapy recovery and bone marrow transplantation), and IA-301 (an HSC expansion platform for bone marrow transplantation and other immune cell types such as T cells). ImmuneAGE has raised $2M to date and is now raising a seed round to further advance these programs. The company operates from San Juan, Puerto Rico and Lausanne, Switzerland and collaborates with teams at the University of Oxford and University of Lausanne.

Participated · Equity · Nov 2023

BeeX develops autonomous underwater drones designed to perform recurrent, regulation-compliant inspections that are cheaper than conventional methods. Its drones have been deployed across Asia-Pacific and Europe to serve offshore wind, oil and gas, subsea cable operators and coastal infrastructure managers. The company also pursues defence applications, including a partnership with Singapore’s Ministry of Defence for national security uses. BeeX is headquartered in Singapore and focuses on expanding operational reach and technological capabilities to meet commercial and defence demand. The recent US$7.7 million Series A will fund fleet expansion and further capability development.